source
- Sanofi eyes 'moonshot' drug acquisitions to offset upcoming Dupixent patent lossSanofi's CFO Francois-Xavier Roger told Fierce that the company is looking at 'moonshot' treatments as potential acquisition targets to rebuild its pipeline. The push comes as the U.S. patent on D…
- Aspen Neuroscience raises $140M IPO to advance Parkinson’s cell therapyAspen Neuroscience, a San Diego biotechnology company, completed an initial public offering, selling roughly 9.4 million shares at $15 each and raising about $140.6 million. The capital will be di…